1421373-99-0

Basic information

• Product Name: AZ 7550
• Synonyms: AZ7551 HCl;AZ7550 salt formate;Osimertinib Impurity 31;Osimertinib N desmethyl impurity 1;2-Propenamide, N-[4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[methyl[2-(methylamino)ethyl]amino]phenyl]-
• CAS NO: 1421373-99-0
• Molecular Formula: C₂₇H₃₁N₇O₂
• Molecular Weight: 485.58074
• EINECS: -0
• Mol File: 1421373-99-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AZ 7550(CAS DataBase Reference)
• NIST Chemistry Reference: AZ 7550(1421373-99-0)
• EPA Substance Registry System: AZ 7550(1421373-99-0)

Safety Data

• Hazardous Substances Data: 1421373-99-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
AZ 7550 is used as an impurity in the production of Osimertinib for its role in the treatment of nonsmall-cell lung cancer (NSCLC). The presence of AZ 7550 in Osimertinib may affect the drug's efficacy, safety, and overall quality, making it crucial to monitor and control its levels during the manufacturing process.
AZ 7550 is used as a reference substance for the development and validation of analytical methods to ensure the purity and quality of Osimertinib. This helps in the accurate determination of the drug's potency and safety, ultimately contributing to the effective treatment of nonsmall-cell lung cancer (NSCLC) patients.

Upstream product

• 1421372-94-2 N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1421373-33-2 tert-butyl N-[2-[[5-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-(prop-2-enoylamino)phenyl](methyl)amino]ethyl]-N-methylcarbamate 
• 1421373-34-3 tert-butyl (2-((2-amino-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate 
• 1421373-35-4 tert-butyl (2-((5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-nitrophenyl)(methyl)amino)ethyl)(methyl)carbamate 
• 120-72-9 indole 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 603-76-9 1-methylindole 

Relevant articles and documents

EGFR specific recognization fluorescent compound as well as preparation method and application thereof

The invention provides an EGFR specific recognization fluorescent compoundrepresented by a general formula I as well as preparation method and application thereof. The fluorescent compound can specifically recognize EGFR mutation and can be applied to specific detection of molecular typing of tumor cells, so that effective diagnosis and curative effect monitoring can be performed on tumor patients.

Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide

Epidermal growth factor receptor (EGFR) is one of the important and valuable drug targets. Overexpression of EGFR is associated with the development of many types of cancer. In this study, three PROTACs small molecules (16a–16c) were designed, synthesized and evaluated for their cytotoxicity against the growth in different NSCLC cell line and the degradation effect. The bioassay results indicated that 16c has a good inhibition in PC9 cells and H1975 cells, and the corresponding IC50 value was 0.413 μM and 0.657 μM, respectively. Western blotting results demonstrated that compound 16c could serve as an effective EGFRdel19-targeting degrader in PC9 cells.

Compound for targeting decomposition of EGFR proteins and preparing method and application of compound

The invention discloses a compound for targeting decomposition of EGFR proteins with a structure shown in a formula or a pharmaceutically acceptable salt of the compound. In the formula, R representsC1-C6 alkyl groups, m is an integer of 1-7, and n is an integer of 1-6. The invention further discloses a preparing method of the compound, a drug composition comprising the compound or the pharmaceutically acceptable salt of the compound and a pharmaceutically acceptable carrier and a preparation prepared from the drug composition. The compound shows an excellent EGFR degradation effect and goodanti-tumor activity. Therefore, the invention further discloses application of the compound in preparing drugs for preventing or/and treating cancers. The compound has a huge application prospect in the field of medical treatment.

HETEROARYL COMPOUNDS FOR KINASE INHIBITION

Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.